You are on page 1of 2

APAC 55% CANCER

OF THE GLOBAL
ACCOUNTS FOR BURDEN

Global China India Japan Korea Thailand Australia Malaysia

# of cancer
patients
14,067,894 3,065,438 1,014,934 703,863 219,520 123,801 122,031 37,426

Cancer mortality
8,202,000 2,205,946 682,830 378,636 81,510 84,981 43,403 21,678

SIGNIFICANT SCIENTIFIC ADVANCES ARE BEING


MADE IN CANCER MEDICINE DEVELOPMENT
Robust pharmaceutical research and development for new cancer products continues.

# of Pipeline Cancer Compounds Globally 445 150

Trial Phase Phase II Phase III

MORE NEEDS TO BE DONE TO ENHANCE


ACCESS TO CANCER MEDICINES
The European Medicines Agency (EMA) approved Morever, there is a lag in the time these medicines
40 cancer medicines between 2009-2014, but only receive approvals compared to the European Union.
a portion is approved in APAC.
Average delay in approval relative to EMA (# of months)
40 32 32 31 26 22 18 18 12 5
12

12 18 19

Taiwan Thailand Malaysia Malaysia Thailand

Note: China is excluded since very few products are approved.


Even fewer of these life-saving or life extending cancer medicines are reimbursed in APAC.

40 30 34 23 22 15 11 10 4 0 0 0

Germany UK France Canada Japan Australia Korea Taiwan Malaysia India China Thailand

Reimbursement decisions of these cancer medicines take longer in APAC.


Average time to reimbursement after approval (# of months)

Note:
2.3 Japan
x China reimbursement system
does not usually include
innovative cancer medicines 3.4 Germany
x India has no national
reimbursement system
for medicines 3.9 UK

8.9 France

17.4 Australia

19.1 Taiwan

27.8 Korea

43.3 Malaysia

CONCLUSION
Barriers to cancer medicine access persist in APAC countries. In order to ensure patients have
timely access to the latest life saving and life-extending innovations, governments in APAC need to:

Increase investments in cancer prevention, diagnosis and treatment


Develop more efficient regulatory pathways to ensure the “drug lag” in APAC is minimized
Streamline reimbursement review processes to minimize the "patient access lag"
to innovative oncology medicines
Identify innovative pathways to fund cancer medicines in markets without reimbursement systems

* Data from IMS research (March 2016)